title: [Personalized peptide vaccination].
abstract: We conducted personalized peptide vaccination (PPV) for various types of advanced cancers in the past 10 years. A maximum of four HLA-matched peptides, which were selected based on the pre-existing host immunity before vaccination, were subcutaneously administered at PPV trials. Randomized phase II trial for patients with castration resistant prostate cancer showed the favorite clinical responses in the PPV group. PPV was also conducted for recurrent or progressive glioblastoma multiforme patients with median overall survival of 10.6 months, resulting in the initiation of randomized phase III clinical trial. A randomized phase III trial is essential to prove clinical benefits of PPV.
authors.affiliation: Department of Immunology and Immunotherapy, Kurume University School of Medicine.
authors.forename: Kyogo
authors.initials: K
authors.lastname: Itoh
authors.forename: Ryuji
authors.initials: R
authors.lastname: Takahashi
authors.forename: Munehiro
authors.initials: M
authors.lastname: Yoshitomi
authors.forename: Mizuhiko
authors.initials: M
authors.lastname: Terasaki
authors.forename: Masanori
authors.initials: M
authors.lastname: Noguchi
mesh_terms: D019496:Cancer Vaccines / Q000276:immunology / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy* / Q000276:immunology / Q000401:mortality; D010446:Peptide Fragments / Q000276:immunology / Q000627:therapeutic use*; D057285:Precision Medicine / Q000379:methods*; D016896:Treatment Outcome
chemical_list: D019496:Cancer Vaccines; D010446:Peptide Fragments